Windward Bio AG is a Switzerland-based company primarily engaged in the biotechnology and biopharmaceutical industry. The Company focuses on the development of ultra-long-acting antibody medicines for immunological, respiratory, and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Their key product is WIN378, which is a monoclonal antibody therapeutic that targets thymic stromal lymphopoietin (TSLP). It aims to reduce inflammation associated with respiratory diseases and provide longer dosing intervals for patients. The Company is also developing WIN027, a bispecific antibody targeting TSLP and interleukin-13 (IL-13) for immunological disorders.
Símbolo de cotizaciónWWB
Nombre de la empresaWindward Bio AG
Fecha de salida a bolsaNov 13, 2026
Director ejecutivoSantarelli (Luca)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
DirecciónAeschenplatz 6
CiudadBASEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal4052
Teléfono41615517575
Sitio Webhttps://windwardbio.com/
Símbolo de cotizaciónWWB
Fecha de salida a bolsaNov 13, 2026
Director ejecutivoSantarelli (Luca)